Switch theme
Sign up to access all valuation multiples
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
2015
169
LTM Revenue $85.1M
LTM EBITDA -$123M
-$127M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Keros Therapeutics has a last 12-month revenue (LTM) of $85.1M and a last 12-month EBITDA of -$123M.
In the most recent fiscal year, Keros Therapeutics achieved revenue of $3.5M and an EBITDA of -$186M.
Keros Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Keros Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $85.1M | XXX | $3.5M | XXX | XXX | XXX |
| Gross Profit | $85.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$123M | XXX | -$186M | XXX | XXX | XXX |
| EBITDA Margin | -145% | XXX | -5234% | XXX | XXX | XXX |
| EBIT | -$146M | XXX | -$210M | XXX | XXX | XXX |
| EBIT Margin | -171% | XXX | -5904% | XXX | XXX | XXX |
| Net Profit | -$112M | XXX | -$187M | XXX | XXX | XXX |
| Net Margin | -132% | XXX | -5278% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Keros Therapeutics's stock price is $14.
Keros Therapeutics has current market cap of $575M, and EV of -$127M.
See Keros Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$127M | $575M | XXX | XXX | XXX | XXX | $-3.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Keros Therapeutics has market cap of $575M and EV of -$127M.
Keros Therapeutics's trades at -35.9x EV/Revenue multiple, and 0.7x EV/EBITDA.
Equity research analysts estimate Keros Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Keros Therapeutics has a P/E ratio of -5.1x.
See valuation multiples for Keros Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $575M | XXX | $575M | XXX | XXX | XXX |
| EV (current) | -$127M | XXX | -$127M | XXX | XXX | XXX |
| EV/Revenue | -1.5x | XXX | -35.9x | XXX | XXX | XXX |
| EV/EBITDA | 1.0x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | 0.9x | XXX | 0.6x | XXX | XXX | XXX |
| EV/Gross Profit | -1.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.1x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKeros Therapeutics's last 12 month revenue growth is 48%
Keros Therapeutics's revenue per employee in the last FY averaged $21K, while opex per employee averaged $1.3M for the same period.
Keros Therapeutics's rule of 40 is -100731% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Keros Therapeutics's rule of X is -24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Keros Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 48% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -145% | XXX | -5234% | XXX | XXX | XXX |
| EBITDA Growth | -59% | XXX | -93% | XXX | XXX | XXX |
| Rule of 40 | -100731% | XXX | -5186% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $21K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4891% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 6004% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Keros Therapeutics acquired XXX companies to date.
Last acquisition by Keros Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Keros Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Keros Therapeutics founded? | Keros Therapeutics was founded in 2015. |
| Where is Keros Therapeutics headquartered? | Keros Therapeutics is headquartered in United States of America. |
| How many employees does Keros Therapeutics have? | As of today, Keros Therapeutics has 169 employees. |
| Who is the CEO of Keros Therapeutics? | Keros Therapeutics's CEO is Dr. Jasbir Seehra, PhD. |
| Is Keros Therapeutics publicy listed? | Yes, Keros Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Keros Therapeutics? | Keros Therapeutics trades under KROS ticker. |
| When did Keros Therapeutics go public? | Keros Therapeutics went public in 2020. |
| Who are competitors of Keros Therapeutics? | Similar companies to Keros Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Keros Therapeutics? | Keros Therapeutics's current market cap is $575M |
| What is the current revenue of Keros Therapeutics? | Keros Therapeutics's last 12 months revenue is $85.1M. |
| What is the current revenue growth of Keros Therapeutics? | Keros Therapeutics revenue growth (NTM/LTM) is 48%. |
| What is the current EV/Revenue multiple of Keros Therapeutics? | Current revenue multiple of Keros Therapeutics is -1.5x. |
| Is Keros Therapeutics profitable? | Yes, Keros Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Keros Therapeutics? | Keros Therapeutics's last 12 months EBITDA is -$123M. |
| What is Keros Therapeutics's EBITDA margin? | Keros Therapeutics's last 12 months EBITDA margin is -145%. |
| What is the current EV/EBITDA multiple of Keros Therapeutics? | Current EBITDA multiple of Keros Therapeutics is 1.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
